Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E.

Lancet. 2000 May 6;355(9215):1575-81.

PMID:
10821360
2.

Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.

Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R; ACE Inhibitors Collaborative Group..

Lancet. 2002 Oct 5;360(9339):1037-43. Review. Erratum in: Lancet 2003 Jan 4;361(9351):90.

PMID:
12383982
3.
5.

Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA; VALIANT Investigators..

Circulation. 2005 Nov 29;112(22):3391-9.

6.
7.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
9.
10.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees..

Lancet. 2003 Sep 6;362(9386):767-71.

PMID:
13678869
12.

Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.

Tsuchihashi-Makaya M, Furumoto T, Kinugawa S, Hamaguchi S, Goto K, Goto D, Yamada S, Yokoshiki H, Takeshita A, Tsutsui H; JCARE-CARD Investigators..

Hypertens Res. 2010 Mar;33(3):197-202. doi: 10.1038/hr.2009.199.

PMID:
19960016
14.

Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.

Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS.

Am J Med. 2000 Oct 1;109(5):371-7.

PMID:
11020393
15.
17.

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC.

N Engl J Med. 1995 Dec 21;333(25):1670-6.

18.

Angiotensin-converting enzyme inhibitors post-myocardial infarction.

Young JB.

Cardiol Clin. 1995 Aug;13(3):379-90. Review.

PMID:
7585774
19.

National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.

Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM.

Circulation. 2004 Aug 10;110(6):724-31.

20.

Supplemental Content

Support Center